ERBB2 and breast cancer: Indeed, Notch1 signaling sustained the survival of a CSC-enriched population following the inhibition of mTOR pathway in TNBC cell models [136], and likewise, it maintained the self-renewal of a population of CSCs resistant to the trastuzumab-based therapy in HER2-positive breast cancer by repressing PTEN [137].